Ojjaara (momelotinib)

Share a patient case

Thank you for taking the time to walk us through one of your patients treated with OJJAARA.

There are five questions, covering the patient’s background before treatment, what led you to start them on OJJAARA, and how they were doing at around the 24-week mark.

©2026 GSK group of companies or its licensor.

Trade marks are owned by or licensed to the GSK group of companies.

GSK